AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants with type 1 diabetes mellitus (T1DM) during continuous subcutaneous infusion (CSII)
Epistemonikos ID: 6552b3226338433173fd1245d43ca35e55a5bbf1
First added on: May 09, 2024